| Serra-Aracil et al 80 | de'Angelis et al 81 | Rouanet et al 82 | Muratore et al 83 | Perdawood et al 84 | Rink et al 85 | Rasulov et al 86 | |
|---|---|---|---|---|---|---|---|
| Study period | 9/2012–9/2014 | 1/2011–12/2014 | 1/2009–6/2011 | 1/2012–12/2013 | 12/2013–4/2015 | 5/2013–3/2015 | 10/2013–1/2015 |
| Study location | Barcelona, Spain | Creteil, France | Montpelier, France | Candiolo, Italy | Slagelse, Denmark | Leverkusen and Mainz, Germany | Moscow, Russia |
| Number of institutions | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Transanal device used | TEO | GelPOINT | TEO | SILS | GelPOINT | GelPOINT or SILS | TEO |
| Total number of patients | 32 | 32 | 30 | 26 | 25 | 24 | 22 |
| Patient and tumor characteristics | |||||||
| Male gender, n (%) | 24 (75) | 21 (66) | 30 (100) | 16 (62) | 19 (76) | 18 (75) | 11 (50) |
| Age, mean ± SD or median (range), y | 68 (39–88) | 64.9 ± 10.0 | 65 (43–82) | 65.8 (38–84) | 70 (54–76) | 57 (35–77) | 56 (30–69) |
| Body mass index, mean ± SD or median (range), kg/m 2 | 25 (20–35) | 25.2 ± 3.5 | 26.0 (21.0–32.4) | 26.2 (16.9–38.2) | 28 (18–46) | 25 (19–38) | 26 (20–32) |
| Tumor height, mean ± SD or median (range), cm | From AV 8 (5–10) |
From AV 4 (2.5–5) |
From LA 1 (0–7) |
From AV 4.4 (3–6) |
From AV 8 (4–10) |
From AV 5 (3–6) |
From AV 6.5 (0–10) |
| Preoperative stage, n (%) | |||||||
| T1–2 | All T1–T3 | 13 (41) | 2 (6) | 2 (8) | 4 (16) | 7 (29) | 5 (23) |
| T3 | 17 (53) | 21 (70) | 6 (23) | 19 (76) | 16 (67) | 14 (64) | |
| T4 | 2 (6) | 7 (23) | 18 (69) | 2 (8) | 1 (4) | 3 (13) | |
| Neoadjuvant therapy, n (%) | 16 (50) | 27 (84) | 26 (87) | 19 (73) | 7 (28) | 19 (79) | 19 (87) |
| Clinical outcomes | |||||||
| Total operative time, mean ± SD or median (range), min | 240 (165–360) | 195 ± 43.6 | 304 (120–500) | 241 (150–360) | 300 (235–420) | 339 (183–458) | 320 (265–495) |
| Conversions, n (%) | 0 | 1 (3) | 2 (7) | 0 | 0 | – | 1 (5) |
| Overall morbidity at 28 d, n (%) | 10 (31) | 8 (25) | 9 (30) | 7 (27) | 13 (52) | 7 (29) | 8 (36) |
| Overall mortality at 28 d, n (%) | 0 | 0 | 0 | 1 (4) | 0 | 0 | 0 |
| Anastomotic leak, % | 3 (9) | 2 (6) | 1 (3) | 2 (8) | 2 (8) | 1 (4) | 0 |
| Unplanned reoperation, % | 0 | – | 2 (7) | – | – | – | 0 |
| Length of hospital stay, mean ± SD or median (range), d | 8 (4–20) | 7.8 ± 2.1 | 14 (9–25) | 7 (3–25) | 5 (2–43) | – | 8 (6–18) |
| Pathological outcomes | |||||||
| Positive CRM, n (%) | 0 | 1 (3) | 4 (13) | 0 | 1 (4) | 2 (8) | 1 (5) |
| Positive DRM, n (%) | 0 | 2 (6.2) | – | 0 | – | 0 | 0 |
| TME quality, n (%) | |||||||
| Complete | 30 (93) | 27 (84) | 30 | 23 (86) | 20 (80) | 22 (92) | 15 (68) |
| Moderate/near-complete | 2 (6) | 3 (9) | 0 | 3 (12) | 5 (20) | 2 (8) | 3 (14) |
| Incomplete | 0 | 2 (6) | 0 | 0 | 0 | 0 | 4 (18) |
| Number of lymph nodes, mean ± SD or median (range) | 15 | 17.1 ± 7.1 | 13 (8–32) | 10 | 21 (9–42) | 14 (4–32) | 17 (0–54) |
| Median follow-up, mo | – | – | 21 | 21 | – | – | 11 |
| Recurrence rate, n (%) | |||||||
| Local | – | – | 4 (13) | 0 | – | – | – |
| Distant | – | – | 8 (27) | 2 (8) | – | – | – |
| Both local and distant | – | – | – | 0 | – | – | – |
Abbreviations: ARJ, anorectal junction; AV, anal verge; CRM, circumferential resection margin; DRM, distal resection margin; LA, levator ani muscles; SD, standard deviation; taTME, transanal total mesorectal excision; TEO, transanal endoscopic operation; TME, transanal endoscopic microsurgery.
Note: In instances with multiple publications on a single cohort, data from most recent publication is shown.
a
Margins < 2 mm defined as positive, all other studies used 1 mm margin.